Similarly in the myeloma study [90] 71.6% of the G-CSF plus plerixafor treated patients collected ≥6 × 106/kg CD34+ cells in ≤2 apheresis procedures versus 34.4% of the G-CSF plus placebo group. The gene discussed is CSF3; the disease is plasma cell myeloma.